BML Capital Management, LLC 13F holdings, Q3 2024
Holdings as of September 30, 2024 · filings on SEC EDGAR · latest filing →
BML Capital Management, LLC disclosed 29 US equity positions worth $169.9m in its Q3 2024 13F filing. The largest position was SGOV at 16.0% of the reported book, followed by TIL and AVIR.
What did BML Capital Management, LLC own in Q3 2024? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | SGOV ISHARES TR | 16.0% | $27.2m | 270,000 | – | ||
| 2 | TIL INSTIL BIO INC | 13.3% | $22.6m | 335,000 | – | ||
| 3 | AVIR ATEA PHARMACEUTICALS INC | Healthcare | 13.1% | $22.3m | 6,650,000 | – | |
| 4 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 9.6% | $16.4m | 14,250,000 | – | |
| 5 | BIL SPDR SER TR | 9.5% | $16.1m | 175,000 | – | ||
| 6 | AVU0 ADVERUM BIOTECHNOLOGIES INC | 9.4% | $15.9m | 2,268,064 | – | ||
| 7 | TECX TECTONIC THERAPEUTIC INC | Healthcare | 3.8% | $6.4m | 211,752 | – | |
| 8 | ANTX AN2 THERAPEUTICS INC | 3.6% | $6.2m | 5,749,432 | – | ||
| 9 | RENEO PHARMACEUTICALS INC | 3.5% | $5.9m | 3,457,395 | – | ||
| 10 | ORMP ORAMED PHARMACEUTICALS INC | 3.1% | $5.3m | 2,186,191 | – | ||
| 11 | 698 ACHILLES THERAPEUTICS PLC | 2.5% | $4.2m | 4,100,002 | – | ||
| 12 | WHWK AADI BIOSCIENCE INC | Healthcare | 2.4% | $4.1m | 2,000,000 | – | |
| 13 | CNTB CONNECT BIOPHARMA HLDGS LTD | 1.8% | $3.0m | 2,093,232 | – | ||
| 14 | PMVP PMV PHARMACEUTICALS INC | 1.5% | $2.5m | 1,688,772 | – | ||
| 15 | ASTROTECH CORP | 1.0% | $1.8m | 220,410 | – | ||
| 16 | MIST MILESTONE PHARMACEUTICALS IN | 1.0% | $1.7m | 1,136,091 | – | ||
| 17 | LENZ LENZ THERAPEUTICS INC | Healthcare | 0.8% | $1.4m | 60,000 | – | |
| 18 | IKENA ONCOLOGY INC | 0.7% | $1.3m | 723,288 | – | ||
| 19 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 0.6% | $1.1m | 228,500 | – | |
| 20 | LSTA LISATA THERAPEUTICS INC | 0.5% | $854.0k | 284,669 | – | ||
| 21 | PIERIS PHARMACEUTICALS INC | 0.4% | $698.5k | 42,130 | – | ||
| 22 | CALC CALCIMEDICA INC | 0.4% | $681.7k | 153,887 | – | ||
| 23 | ALLOVIR INC | 0.3% | $487.6k | 603,086 | – | ||
| 24 | TLIS TALIS BIOMEDICAL CORP | 0.3% | $460.1k | 248,702 | – | ||
| 25 | VTGN VISTAGEN THERAPEUTICS INC | 0.3% | $451.5k | 150,000 | – | ||
| 26 | FBRX FORTE BIOSCIENCES INC | 0.2% | $393.9k | 70,468 | – | ||
| 27 | NXTC NEXTCURE INC | 0.2% | $378.8k | 276,465 | – | ||
| 28 | VRCA VERRICA PHARMACEUTICALS INC | 0.2% | $261.0k | 180,000 | – | ||
| 29 | HILLEVAX INC | 0.0% | $34.8k | 19,760 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.